These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443 [TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830 [TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059 [TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes. Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063 [TBL] [Abstract][Full Text] [Related]
7. What biologic factors predict for transformation to AML? Bejar R Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744 [TBL] [Abstract][Full Text] [Related]
8. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Bernasconi P Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941 [TBL] [Abstract][Full Text] [Related]
9. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276 [TBL] [Abstract][Full Text] [Related]
12. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and classification of myelodysplastic syndromes. Hasserjian RP; Germing U; Malcovati L Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372 [TBL] [Abstract][Full Text] [Related]
14. Novel combinations to improve hematopoiesis in myelodysplastic syndrome. Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634 [TBL] [Abstract][Full Text] [Related]
15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453 [TBL] [Abstract][Full Text] [Related]
16. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis. Matos A; Magalhães SMM; Rauh MJ Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175 [TBL] [Abstract][Full Text] [Related]
17. Biology of the bone marrow microenvironment and myelodysplastic syndromes. Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353 [TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082 [TBL] [Abstract][Full Text] [Related]
19. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience. Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484 [TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview. Jhanwar SC Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]